SE9703414D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9703414D0
SE9703414D0 SE9703414A SE9703414A SE9703414D0 SE 9703414 D0 SE9703414 D0 SE 9703414D0 SE 9703414 A SE9703414 A SE 9703414A SE 9703414 A SE9703414 A SE 9703414A SE 9703414 D0 SE9703414 D0 SE 9703414D0
Authority
SE
Sweden
Prior art keywords
pct
sec
new compounds
date
pub
Prior art date
Application number
SE9703414A
Other languages
English (en)
Inventor
Nils-Aake Bergman
Ambra Thomas D
Garry Pilling
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9703414A priority Critical patent/SE9703414D0/sv
Publication of SE9703414D0 publication Critical patent/SE9703414D0/sv
Priority to ZA988353A priority patent/ZA988353B/xx
Priority to TR2000/00785T priority patent/TR200000785T2/xx
Priority to EEP200000171A priority patent/EE200000171A/xx
Priority to US09/171,779 priority patent/US6127414A/en
Priority to BR9812492-7A priority patent/BR9812492A/pt
Priority to AU92889/98A priority patent/AU9288998A/en
Priority to JP2000512808A priority patent/JP2001517651A/ja
Priority to DE69809782T priority patent/DE69809782T2/de
Priority to PL98339617A priority patent/PL339617A1/xx
Priority to EP98945708A priority patent/EP1017672B1/en
Priority to SK360-2000A priority patent/SK3602000A3/sk
Priority to AT98945708T priority patent/ATE228500T1/de
Priority to PCT/SE1998/001686 priority patent/WO1999015498A1/en
Priority to KR1020007003029A priority patent/KR20010024220A/ko
Priority to CN98811336A priority patent/CN1279666A/zh
Priority to CA002303528A priority patent/CA2303528A1/en
Priority to IL13499398A priority patent/IL134993A0/xx
Priority to ARP980104740A priority patent/AR017138A1/es
Priority to IS5410A priority patent/IS5410A/is
Priority to NO20001483A priority patent/NO20001483L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9703414A 1997-09-23 1997-09-23 New compounds SE9703414D0 (sv)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SE9703414A SE9703414D0 (sv) 1997-09-23 1997-09-23 New compounds
ZA988353A ZA988353B (en) 1997-09-23 1998-09-11 New NPY antagonists
IL13499398A IL134993A0 (en) 1997-09-23 1998-09-21 New npy antagonists
DE69809782T DE69809782T2 (de) 1997-09-23 1998-09-21 Npy antagonisten
SK360-2000A SK3602000A3 (en) 1997-09-23 1998-09-21 New npy antagonists
US09/171,779 US6127414A (en) 1997-09-23 1998-09-21 NPY antagonists
BR9812492-7A BR9812492A (pt) 1997-09-23 1998-09-21 Composto, uso do mesmo, formulação farmacêutica, e, processos para o tratamento de uma doença cardiovascular, para o tratamento de uma vasoconstrição, e para a preparação de compostos
AU92889/98A AU9288998A (en) 1997-09-23 1998-09-21 New npy antagonists
JP2000512808A JP2001517651A (ja) 1997-09-23 1998-09-21 新しいnpy拮抗剤
TR2000/00785T TR200000785T2 (tr) 1997-09-23 1998-09-21 Yeni NPY antagonistleri.
PL98339617A PL339617A1 (en) 1997-09-23 1998-09-21 Novel antagonists of neuropeptide y
EP98945708A EP1017672B1 (en) 1997-09-23 1998-09-21 New npy antagonists
EEP200000171A EE200000171A (et) 1997-09-23 1998-09-21 Uued NPY antagonistid
AT98945708T ATE228500T1 (de) 1997-09-23 1998-09-21 Npy antagonisten
PCT/SE1998/001686 WO1999015498A1 (en) 1997-09-23 1998-09-21 New npy antagonists
KR1020007003029A KR20010024220A (ko) 1997-09-23 1998-09-21 신규한 npy 길항제
CN98811336A CN1279666A (zh) 1997-09-23 1998-09-21 新的npy拮抗剂
CA002303528A CA2303528A1 (en) 1997-09-23 1998-09-21 New npy antagonists
ARP980104740A AR017138A1 (es) 1997-09-23 1998-09-22 Compuestos antagonistas del neuropeptido y, formulaciones farmaceuticas que los incluyen, usos farmaceuticos de tales compuestos y procedimientos parala preparacion de los mismos.
IS5410A IS5410A (is) 1997-09-23 2000-03-20 Ný mótlyf taugapeptíðs Y (NPY)
NO20001483A NO20001483L (no) 1997-09-23 2000-03-22 Nye NPY-agonister

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703414A SE9703414D0 (sv) 1997-09-23 1997-09-23 New compounds

Publications (1)

Publication Number Publication Date
SE9703414D0 true SE9703414D0 (sv) 1997-09-23

Family

ID=20408331

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9703414A SE9703414D0 (sv) 1997-09-23 1997-09-23 New compounds

Country Status (21)

Country Link
US (1) US6127414A (sv)
EP (1) EP1017672B1 (sv)
JP (1) JP2001517651A (sv)
KR (1) KR20010024220A (sv)
CN (1) CN1279666A (sv)
AR (1) AR017138A1 (sv)
AT (1) ATE228500T1 (sv)
AU (1) AU9288998A (sv)
BR (1) BR9812492A (sv)
CA (1) CA2303528A1 (sv)
DE (1) DE69809782T2 (sv)
EE (1) EE200000171A (sv)
IL (1) IL134993A0 (sv)
IS (1) IS5410A (sv)
NO (1) NO20001483L (sv)
PL (1) PL339617A1 (sv)
SE (1) SE9703414D0 (sv)
SK (1) SK3602000A3 (sv)
TR (1) TR200000785T2 (sv)
WO (1) WO1999015498A1 (sv)
ZA (1) ZA988353B (sv)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802075D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
US6312898B1 (en) * 1999-04-15 2001-11-06 Hormos Medical Oy, Ltd. Diagnosis of a person's risk of developing atherosclerosis or diabetic retinopathy based on leucine 7 to proline 7 polymorphism in the prepro-neuropeptide Y gene
SE9902596D0 (sv) * 1999-07-06 1999-07-06 Astra Ab Pharmaceutically active compounds
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
SE0101328D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Therapeutic treatment
WO2002092566A1 (fr) * 2001-05-15 2002-11-21 Taisho Pharmaceutical Co.,Ltd. Derives d'arginine
EP1620091B1 (en) 2003-05-05 2010-03-31 Probiodrug AG Inhibitors of glutaminyl cyclase
EP1680120A2 (en) 2003-11-03 2006-07-19 Probiodrug AG Combinations useful for the treatment of neuronal disorders
FR2864830B1 (fr) * 2004-01-06 2006-03-10 Centre Nat Rech Scient Procede de synthese sur support solide de composes peptidiques, notamment de composes peptidiques comportant un residu arginine
KR101099206B1 (ko) 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
FR2884516B1 (fr) * 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
KR100689499B1 (ko) * 2005-10-26 2007-03-02 삼성전자주식회사 휴대단말기에서 키 설정 정보 디스플레이 방법
WO2007064272A1 (en) * 2005-11-29 2007-06-07 Astrazeneca Ab Benzhydryl amide derivatives as cannabinoid receptor antagonists or inverse agonists
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
DK2686313T3 (en) 2011-03-16 2016-05-02 Probiodrug Ag Benzimidazole derivatives as inhibitors of glutaminyl cyclase
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5873821A (en) * 1992-05-18 1999-02-23 Non-Invasive Technology, Inc. Lateralization spectrophotometer
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544686A1 (de) * 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544687A1 (de) * 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP2000501107A (ja) * 1996-01-09 2000-02-02 イーライ・リリー・アンド・カンパニー ベンズイミダゾリル神経ペプチドy受容体アンタゴニスト
JP4106711B2 (ja) * 1996-03-21 2008-06-25 萬有製薬株式会社 アミノピリジン誘導体
EP1007073A4 (en) * 1996-06-04 2002-03-27 Synaptic Pharma Corp METHODS OF MODIFYING FOOD BEHAVIOR, COMPOUNDS USEFUL IN SAID METHODS, AND DNA ENCODING A HYPOTHALAMIC NEUROPEPTIDE Y / PEPTIDE YY Y5 RECEPTOR
EP0918761B1 (en) * 1996-07-23 2003-05-02 Neurogen Corporation Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands
DK0915859T3 (da) * 1996-07-23 2003-03-03 Neurogen Corp Visse substituerede benzylaminderivater; en ny klasse af Neuropeptid Y1-specifikke ligander
JP2000515151A (ja) * 1996-07-23 2000-11-14 ニューロジェン・コーポレーション 特定の置換ベンジルアミン誘導体;新規クラスの神経ペプチド―y1特異的リガンド
US6849733B1 (en) * 1996-08-23 2005-02-01 Agouron Pharmaceuticals, Inc. Neuropeptide-Y ligands
US6043246A (en) * 1996-12-03 2000-03-28 Banyu Pharmaceutical Co., Ltd. Urea derivatives
AU5410498A (en) * 1996-12-12 1998-07-03 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
US6166038A (en) * 1996-12-13 2000-12-26 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
AU7738198A (en) * 1996-12-15 1998-07-15 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
AU733883B2 (en) * 1997-02-04 2001-05-31 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
JP2000510870A (ja) * 1997-02-14 2000-08-22 バイエル・コーポレーシヨン Npy5受容体アンタゴニストとしてのアミド類
JP2002241368A (ja) * 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
AU6309698A (en) * 1997-03-12 1998-09-29 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
US5889016A (en) * 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists

Also Published As

Publication number Publication date
IS5410A (is) 2000-03-20
US6127414A (en) 2000-10-03
JP2001517651A (ja) 2001-10-09
SK3602000A3 (en) 2001-01-18
TR200000785T2 (tr) 2000-09-21
NO20001483L (no) 2000-05-23
EP1017672A1 (en) 2000-07-12
AR017138A1 (es) 2001-08-22
PL339617A1 (en) 2001-01-02
AU9288998A (en) 1999-04-12
NO20001483D0 (no) 2000-03-22
EE200000171A (et) 2001-04-16
WO1999015498A1 (en) 1999-04-01
DE69809782T2 (de) 2003-07-17
DE69809782D1 (de) 2003-01-09
BR9812492A (pt) 2000-09-26
IL134993A0 (en) 2001-05-20
EP1017672B1 (en) 2002-11-27
KR20010024220A (ko) 2001-03-26
ZA988353B (en) 1999-03-23
CA2303528A1 (en) 1999-04-01
ATE228500T1 (de) 2002-12-15
CN1279666A (zh) 2001-01-10

Similar Documents

Publication Publication Date Title
SE9703414D0 (sv) New compounds
BG101112A (en) The use of heterocyclic compounds
DK1000035T3 (da) Substituerede 6-phenylphenanthridiner
BR9502708A (pt) Compostos bem como composiçao farmaceutica comprendendo os mesmos
YU29503A (sh) Novi antiholinergici koji se mogu primeniti kao lekovi, kao i postupak za njihovo dobijanje
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
BR9707233A (pt) Fenantridinas
TR199901653T2 (xx) Fitalazinonlar.
DE59509846D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
NZ516599A (en) 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
DE60045508D1 (de) Dalda-analoge und ihre verwendung
DE59510370D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
FR2712591B1 (fr) Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
BG105710A (en) 5ht1 antagonists for antidepressant therapy
CO4410330A1 (es) Nuevos derivados de bencimidazol farmacologicamente activos y sus sales de adicion acida
ATE242236T1 (de) N-substituierte 3-azabicyclo(3.2.0)heptan- derivate als neuroleptika
ATE213731T1 (de) Chinoxalinderivate und ihre therapeutische verwendbarkeit
ES2094545T3 (es) Derivados n-substituidos del 3-azabiciclo(3.2.0)heptano, como neurolepticos etc..
HUP0100781A2 (hu) A jóindulatú prosztata hiperplázia kezelésére alkalmas szubsztituált piridino aril piperazin-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
SE9902387D0 (sv) New pharmaceutically active compounds
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
TR200100475T2 (tr) N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları.
SE9902596D0 (sv) Pharmaceutically active compounds
DE69403896D1 (de) 4-amino-2-(hetero)aryl-butanamide verwenbar als 5-ht1a-antagonisten